JPRN-UMIN000000719已完成未知
Combination therapy of 5-Fluorouracil/gemcitabine/cisplatin for advanced hepatocellular carcinoma with extrahepatic metastases -A pilot study- - Combination therapy of 5FU/gemcitabine/CDDP for advanced HCC with extrahepatic metastases -A pilot study
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •With other malignant disease. A pregnant woman, or a woman suspected of pregnancy. With severe infectious disease. With history of severe allergy. With severe renal function disease. With S-1. With severe allergy for 5FU, gemcitabine, or CDDP. With severe bone marrow supression. With pulmonary fibrosis. With the history of radiotharpy for lung.
研究者
相似试验
进行中（未招募）
1 期
Combination therapy of 5-Fluorouracil and Calcipotriol versus 5-Fluorouracil in the treatment of Actinic Keratosis: a multicentre randomized controlled clinical trialActinic KeratosisCTIS2024-511409-42-00niversity Hospital Maastricht232
尚未招募
4 期
ocal application of drug 5- FLUOROURACIL as a Medication THERAPY following removal of tumour called AMELOBLASTOMACTRI/2024/03/064106Dr Priyanka Shetty
尚未招募
4 期
A study on local application of drug named 5-fluorouracil after removal of cyst by the name of Odontogenic keratocyst in jawsCTRI/2024/03/063854Dr Priyanka Shetty
进行中（未招募）
不适用
Combination of 5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin®) (FLOX regimen) with Concomitant or Concomitant and Maintenance Administration of Cetuximab (Erbitux®), in First-Line Treatment of Metastatic Colorectal Cancer. - Nordic VIIPatient with metastatic colorectal cancer.EUCTR2005-000117-34-ISThe Nordic Colorectal Cancer Biomodulation Group550
进行中（未招募）
不适用
Combination of 5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin®) (FLOX regimen) with Concomitant or Concomitant and Maintenance Administration of Cetuximab (Erbitux®), in First-Line Treatment of Metastatic Colorectal Cancer. - Nordic VIIPatient with metastatic colorectal cancer.EUCTR2005-000117-34-DKThe Nordic Colorectal Cancer Biomodulation Group550